CLGN CollPlant Biotechnologies Ltd
Price (delayed)
$2.5765
Market cap
$29.51M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.45
Enterprise value
$20.68M
collplant is a regenerative medicine company focused on 3d bioprinting of tissues and organs, and on developing and commercializing tissue repair products for orthobiologics, and advanced wound care markets. our
Highlights
The gross margin has grown by 5% from the previous quarter
The debt has contracted by 5% from the previous quarter and by 2.5% YoY
The company's net income has shrunk by 137% YoY but it rose by 4.7% QoQ
The company's EPS has shrunk by 134% YoY but it rose by 6% QoQ
The revenue has plunged by 95% YoY and by 21% from the previous quarter
The equity has plunged by 52% YoY and by 20% from the previous quarter
Key stats
What are the main financial stats of CLGN
Market
Valuations
Earnings
Shares outstanding
11.45M
Market cap
$29.51M
Enterprise value
$20.68M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.19
Price to sales (P/S)
57.3
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
40.16
Revenue
$515,000
Gross profit
-$1.11M
Operating income
-$17.25M
Net income
-$16.61M
EBIT
-$17.25M
EBITDA
-$16.21M
Free cash flow
-$14.58M
Per share
Balance sheet
Liquidity
EPS
-$1.45
EPS diluted
-$1.45
Free cash flow per share
-$1.27
Book value per share
$1.18
Revenue per share
$0.04
TBVPS
$1.62
Total assets
$18.71M
Total liabilities
$5.25M
Debt
$3.08M
Equity
$13.47M
Working capital
$10.21M
Debt to equity
0.23
Current ratio
4.44
Quick ratio
4.21
Net debt/EBITDA
0.54
Margins
Efficiency
Dividend
EBITDA margin
-3,148.2%
Gross margin
-215.5%
Net margin
-3,225%
Operating margin
-3,349.7%
Return on assets
-67.8%
Return on equity
-87.9%
Return on invested capital
-246.3%
Return on capital employed
-109.6%
Return on sales
-3,349.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CLGN stock price
How has the CollPlant Biotechnologies stock price performed over time
Intraday
0.25%
1 week
-4.75%
1 month
-26.39%
1 year
-51.02%
YTD
-28.43%
QTD
-0.14%
Financial performance
How have CollPlant Biotechnologies's revenue and profit performed over time
Revenue
$515,000
Gross profit
-$1.11M
Operating income
-$17.25M
Net income
-$16.61M
Gross margin
-215.5%
Net margin
-3,225%
The company's net income has shrunk by 137% YoY but it rose by 4.7% QoQ
CollPlant Biotechnologies's operating income has shrunk by 130% YoY but it has increased by 6% QoQ
CLGN's gross profit has plunged by 112% YoY but it is up by 25% from the previous quarter
The revenue has plunged by 95% YoY and by 21% from the previous quarter
Growth
What is CollPlant Biotechnologies's growth rate over time
Valuation
What is CollPlant Biotechnologies stock price valuation
P/E
N/A
P/B
2.19
P/S
57.3
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
40.16
The company's EPS has shrunk by 134% YoY but it rose by 6% QoQ
The equity has plunged by 52% YoY and by 20% from the previous quarter
The P/B is 48% less than the 5-year quarterly average of 4.2 and 24% less than the last 4 quarters average of 2.9
The revenue has plunged by 95% YoY and by 21% from the previous quarter
CLGN's price to sales (P/S) is 11% lower than its last 4 quarters average of 64.0 and 8% lower than its 5-year quarterly average of 62.1
Efficiency
How efficient is CollPlant Biotechnologies business performance
The company's return on sales fell by 21% QoQ
CollPlant Biotechnologies's ROE has decreased by 14% from the previous quarter
CLGN's ROA is down by 10% since the previous quarter
The ROIC has grown by 2.9% from the previous quarter
Dividends
What is CLGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CLGN.
Financial health
How did CollPlant Biotechnologies financials performed over time
The quick ratio has contracted by 49% YoY and by 18% from the previous quarter
The current ratio has declined by 48% year-on-year and by 17% since the previous quarter
The debt is 77% less than the equity
CollPlant Biotechnologies's debt to equity has surged by 109% YoY and by 21% QoQ
The equity has plunged by 52% YoY and by 20% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.